NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs031220199

Registered date:08/07/2022

Efficacy and Safety of MeLeu in patients with pancreatic cancer

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedPancreatic cancer
Date of first enrollment06/09/2022
Target sample size20
Countries of recruitment
Study typeInterventional
Intervention(s)Positron emission tomography study using probe of [11C]MeLeu

Outcome(s)

Primary OutcomeThe following points related to diagnostic performance will be evaluated and examined using PET/CT images including the pancreatic cancer lesion of [11C]MeLeu. # Ability to visualize pancreatic cancer # Administered radioactivity # Exploratory for the optimal conditions on PET imaging procedure
Secondary Outcome1.Comparison of PET/CT images of the abdomen including pancreatic cancer lesions of [18F] FDG and the ability to visualize pancreatic cancer 2.Evaluation of adverse events 3.Examination of association with SLC6A20, a blood transporter protein

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria1.Subjects who are 18 years of age or older at the time of consent acquisition 2.Subjects who have been confirmed to have pancreatic cancer by histopathological or clinical examination 3.Subjects who have performed or are scheduled to perform [18F]FDG PET/CT by insurance within 30 days before or after the date of obtaining [11C]MeLeu PET/CT imaging, if [18F]FDG PET/CT imaging information is to be used 4.Subjects whose Performance Status (ECOG PS) is 0 or 1 5.Subjects who provide written informed consent
Exclude criteria1.Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co-investigator to be unsuitable for this study 2.Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urinalysis) after obtaining the informed consent 3.Subjects with drug addiction or alcohol addiction 4.Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study 5.Subjects who are unable or restricted from the tests specified in the research plan 6.Subjects who are claustrophobic 7.Subjects who are considered to be inappropriate to participate in this study by the investigator or co-investigator

Related Information

Contact

Public contact
Name Kana Yamazaki
Address 4-9-1 Anagawa Inage-ku Chiba-shi Chiba, Japan Chiba Japan 263-8555
Telephone +81-43-206-3402
E-mail yamazaki.kana@qst.go.jp
Affiliation National Institutes for Quantum Science and Technology
Scientific contact
Name Kana Yamazaki
Address 4-9-1 Anagawa Inage-ku Chiba-shi Chiba, Japan Chiba Japan 263-8555
Telephone +81-43-206-3402
E-mail yamazaki.kana@qst.go.jp
Affiliation National Institutes for Quantum Science and Technology